PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (CEO)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (CEO) (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and GERALD MCMAHON (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and RONALD MARTELL (the “Executive”).
ContractCommercial Picoplatin Active Pharmaceutical Ingredient Manufacturing Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
*** Indicates confidential material that has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been separately filed with the Securities and Exchange Commission.
